Hepatic ischemia reperfusion (IR) injury is an important clinical issue and its mechanism not fully clear. Nitric oxide (NO) has become the subject of both intense research as well as heated debate over its role in various biological and pathophysiological processes since its discovery. The role of NO during hepatic I/R still largely contradictory. Increasing evidences indicate that hepatic IR injury involve in leukotriene (LT). LTs are arachidonic acid-derived metabolites that are synthesized via the 5-lipoxygenase pathway. That the LTC4 synthase (LTC4S) catalyzes LTA4 and reduced glutathione to generate LTC4 is the first committed step in the synthesis of cysteinyl LTs, LTC4, LTD4 and LTE4. Our previous series of findings suggest: 1.abnormal LTC4 accumulation after hepatic IR can be caused partially by LTC4S expression up-regulation and the LTC4S activity augment. 2.that sodium nitroprusside(SNP), a NO donor decrease LTC4 production during hepatic IR could be partially resulted from SNP down-regulating the protein expression of LTC4S rather than mGST2 or mGST3 and its suppression of the LTC4S activity. 3.SNP downregulated LTC4S mRNA expression by inhibiting NF-kB activation independent of IkBa. However, there is no literature that studied the relationships among the abnormal increased LTC4 production and the changes in the mRNA and protein expression,distribution and activity of 5-lipoxygenase, as well as the direct and indirect effects of NO donor on them during hepatic IR injury in rats. Here using in vivo rat model of 70% hepatic IR injury and in vitro model of liver slice hypoxygen/reoxygenation, we will concentrate on the following topics: 1.How about the relationships between the abnormal increased LTC4 production and the changes in the expression,distribution and activity of 5-lipoxygenase? Did the abnormal increased LTC4 production come from the increased LTA4 synthesis via the 5-LO/LTC4S pathway or just from the up-regulated expression and activity of LTC4S?2. How about the relationship among NO donor induced decrease of LTC4 synthesis, the changes in the expression,distribution and activity of 5-lipoxygenase,as well as the 3-nitrotyrosine formation of 5-LO and LTC4S? Did the NO donor induced supression of LTC4 synthesis come from NO decreasing LTA4 synthesis via the 5-LO/LTC4S pathway or just from NO down-regulating the expression and activity of LTC4S during hepatic IR injury?3. In addition to the above direct effects of NO donor, whether NO donor induced suppression of LTC4 synthesis involved in NO inhibiting 5-LO and/or LTC4S indirectly through activation of the sGC and cGK pathways? All these works if completed will further elucidate the molecular mechanisms underlying the abnormal increased LTC4 production and NO donor inhibiting LTC4 systhesis in the early phase of hepatic IR injury in rats. It will provide some new experimental and theoretic evidence for the treatment of liver transplantation and liver resectional surgery.
白三烯C4(LTC4)是重要的前炎症因子。我们前期报道肝缺血再灌注(IR)早期LTC4异常增加与LTC4合酶(LTC4S)表达和酶活性增加有关;NO供体硝普钠能抑制LTC4S表达和酶活性,减少LTC4堆积,保护肝功能。本课题拟用在体肝IR早期损伤和离体肝切片缺氧/复氧模型,研究①LTC4异常增加与5-脂氧化酶(5-LO)基因和蛋白表达、分布和酶活性的相关性,肝IR是否经5-LO/LTC4S提高LTA4含量增加LTC4合成;②NO供体降低LTC4含量与其对5-LO表达、分布和酶活性的影响及5-LO和LTC4S酪氨酸残基硝化修饰的相关性,NO供体是否经5-LO/LTC4S减少LTA4含量抑制LTC4合成;③NO供体是否间接经激活sGC/cGK,抑制5-LO和/或LTC4S减少LTC4合成。阐释肝IR早期LTC4异常增加及NO供体调控的分子机制。为治疗肝移植和肝肿瘤切除等疾病提供新实验理论依据。
肝脏缺血再灌注(IR)损伤是肝脏外科尚未完全解决的棘手问题。一氧化氮(NO)参与了机体多项生理和病理过程。有关NO在肝脏IR损伤中作用尚不一致。肝IR病理机制中涉及白三烯(LTs)。LTs是经5-脂氧化酶(5-LO)途径产生的重要前炎症花生四烯酸类物质,包括Cys-LT(LTC4, LTD4 and LTE4)和LTB4。Cys-LT母体复合物LTC4经由LTC4S催化LTA4与GSH结合形成。本课题采用经典的在体肝70% IR模型,结合现代药理学和分子生物学技术研究发现:①肝脏IR早期LTC4等Cys-LT显著增加,而LTB4含量未出现明显改变,该结果与5-LO、LTC4S表达增加而LTA4H表达无明显变化相关,表明肝IR可能经5-LO/LTC4S提高LTA4含量增加LTC4等Cys-LT生成;此外,IR组肝脏组织中硝基酪氨酸(NT)(NT)表达明显增强,表明肝脏IR早期生成了大量的ONOO-,可能会通过直接硝化修饰5-LO和LTC4S酪氨酸残基影响LTC4等Cys-LT生成。②中剂量NO供体硝普钠(SNP)可明显降低LTC4等Cys-LT含量,但不改变LTB4含量;中剂量NO供体SNP下调5-LO和LTC4S表达,但对LTA4H表达无明显影响;表明NO供体SNP可能经调节5-LO/LTC4S表达抑制LTC4等Cys-LT生成;同时中剂量NO供体SNP下调肝脏组织中NT的表达提示其可能通过影响5-LO和LTC4S酪氨酸残基硝化修饰造成其活性变化。iNOS选择性抑制剂SMT有类似作用,可能与其影响肝脏IR早期NO生成ONOO-,调节5-LO和LTC4S表达和硝化修饰有关。③在肝脏I/R损伤期间,肝脏特异性NO供体V-PYRRO/NO可以下调LTC4S,其机制可能涉及抑制不依赖于IκB降解的NF-κB信号转导途径;④IP处理减少肝脏I/R期间LTC4 堆积,同时伴随血清肝酶释放减少和肝组织结构损伤降低,以及保护肝组织氧化还原状态,表明IP的有利影响可能涉及其在肝脏I/R损伤期间抑制LTC4 生成。⑤证实IP显著降低肝I/R损伤大鼠肝微粒部分LTC4合成酶的活性,表明IP降低LTC4生成可能与其在I/R过程中抑制肝LTC4合成酶的活性有关。这些实验结果进一步阐释了肝IR早期LTC4异常增加及NO供体和IP调控的分子机制。为治疗肝移植和肝肿瘤切除等疾病提供新实验理论依据。
{{i.achievement_title}}
数据更新时间:2023-05-31
坚果破壳取仁与包装生产线控制系统设计
SRHSC 梁主要设计参数损伤敏感度分析
肝脏多b值扩散心率因素的评价
考虑损伤影响的混凝土层裂试验与数值模拟
基于GEO数据库呼吸机相关性肺损伤小鼠基因芯片数据的生物信息学分析及关键基因验证
基于白三烯C4代谢途径研究肝脏IR损伤致LTC4异常增加及IP调控的分子机制
生长抑素经NHE途径调节肠道水、钠吸收
AAH羟化酶活性介导肝内胆管癌的经淋巴途径转移及分子机制
常温机械灌注抑制DCD供肝分泌CIRP减轻缺血再灌注损伤的机制研究